Search results
Author(s):
Kenji Sunagawa
Added:
6 years ago
Author(s):
On Topaz
,
Allyne Topaz
,
Pritam R Polkampally
Added:
3 years ago
Plaque rupture and subsequent thrombus formation account for most acute myocardial infarctions (AMIs). Percutaneous coronary intervention (PCI) is considered the preferred treatment for ST-segment-elevation myocardial infarction (STEMI), for evolving non-STEMI (NSTEMI) and for rescue intervention post-thrombolytics.1 The main goals of primary and rescue PCI in AMI include restoration of a normal…
View more
Author(s):
Edwin Lee
,
Ajay J Kirtane
Added:
3 years ago
The outcomes of patients with ST-segment elevation myocardial infarction (STEMI) have improved in recent years with the more widespread adoption of definitive reperfusion therapies, including rapid recanalisation of the infarct-related artery with percutaneous coronary intervention (PCI). Nonetheless, despite the near universal restoration of normal epicardial flow following primary PCI for STEMI…
View more
Author(s):
Dan Wichterle
Added:
3 years ago
Myocardial infarction (MI) is associated with acute risk of early malignant arrhythmias that can be easily treated during in-hospital intensive care by defibrillation, adjuvant antiarrhythmic therapy or even catheter ablation in resistant cases. Indeed, such management resulted in substantial improvement in MI survival rate. Despite the implementation of primary percutaneous coronary…
View more
Author(s):
Robert H Christenson
Added:
3 years ago
Accurate and timely biochemical marker testing for aiding the diagnosis of myocardial infarction (MI) has been important for the appropriate disposition and treatment of patients for the past several decades. Creatine kinase (CK) muscle and brain (CK-MB) mass and myoglobin measurements were the standard up to the mid-1990s, when assays for the cardiac-specific isoforms of troponin I and troponin…
View more
Author(s):
Lee Chang
,
Robert Yeh
Added:
3 years ago
Cardiogenic shock is the leading cause of death in patients with acute ST-elevation myocardial infarction (STEMI). Characterised by a state of low cardiac output leading to end-organ hypoperfusion, cardiogenic shock complicates approximately 5–8 % of STEMIs and is associated with a mortality rate approaching 50 percent.1–3 Prompt recognition and therapeutic intervention for cardiogenic shock due…
View more
Author(s):
José PS Henriques
Added:
3 years ago
Despite considerable improvements in the treatment of acute ST elevation myocardial infarction (STEMI), outcomes have predominantly improved in STEMI patients without cardiogenic shock (CS). Nevertheless, cardiogenic shock occurs in approximately 7–10% of STEMI patients and is the leading cause of death for hospitalised patients. In-hospital mortality rates of STEMI complicated by CS are around…
View more
Author(s):
Derek P Chew
,
Harvey D White
Added:
3 years ago
The cumulative evidence base informing almost every aspect of myocardial infarction acute coronary syndrome (ACS) care is expansive and has been associated with a decline in the rate of mortality. Within the context of current-era clinical trials of ST-segment-elevation myocardial infarction, 30-day mortality rates of 4–5% have now been reported for high-risk individuals,1,2 with similar rates…
View more
Author(s):
Derek P Chew
,
Harvey D White
Added:
3 years ago
The cumulative evidence base informing almost every aspect of myocardial infarction acute coronary syndrome (ACS) care is expansive and has been associated with a decline in the rate of mortality. Within the context of current-era clinical trials of ST-segment-elevation myocardial infarction, 30-day mortality rates of 4–5% have now been reported for high-risk individuals,1,2 with similar rates…
View more
Author(s):
Tracy Wang
Added:
6 years ago
Tracy Wang discusses the ARTEMIS study - Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction.
Filmed by Radcliffe Cardiology on-site at ACC 2018 in Orlando, FL, US
View more